On september 26, 2018 NANOBIOTIX (Euronext: NANO – ISIN:FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, reported that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, MD, PhD at the ESMO (Free ESMO Whitepaper) 2018 Congress in Munich (Germany) on the 19th of October 2018 during the Proffered Paper (Oral) presentation – Sarcoma and at the ASTRO 60th Annual Meeting in San Antonio (USA) on the 21st of October 2018 during the late-breaking abstract session (Press release, Nanobiotix, SEP 26, 2018, View Source [SID1234529667]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2018 Congress
October 19 – 23, 2018 – Munich, Germany
• A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally
advance soft tissue sarcoma of the extremity and trunk wall (LBA66)
Oral communication presented by Dr. Sylvie Bonvalot, MD, PhD (Paris, France) during the Proffered Paper
presentation – Sarcoma
Date: 10.19.2018
• Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3
nanoparticles activated by radiotherapy: a phase I trial (1058P)
Poster presented by Prof. Christophe Le Tourneau (Paris, France)
Date: 10.21.2018
• Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by
stereotactic body radiation therapy (711P)
Poster presented by Dr. Marc Pracht (Rennes, France)
Date: 10.21.2018
American Society for Radiation Oncology (ASTRO) 60th Annual Meeting
October 21 – 24, 2018 – San Antonio, Texas, United States
• Act.in.Sarc: An International Randomized Phase III Trial Evaluating Efficacy and Safety of First-in-Class
NBTXR3 Hafnium Oxide Nanoparticles Activated by Preoperative Radiotherapy in Locally Advanced
Soft Tissue Sarcoma (LBA7)
Oral communication presented by Dr. Sylvie Bonvalot, MD, PhD (Paris, France) during the late-breaking abstract
session
Date: 10.23.2018
• Hafnium Oxide Nanoparticles Activated by Radiation Therapy for the Treatment of Solid Tumors
(SU_44_2434)
Poster presented by Prof. Juliette Thariat, MD, PhD (Caen, France)
Date: 10.21.2018
• Hafnium Oxide Nanoparticles Activated by Radiation Therapy: An Innovative Approach for the
Treatment of Liver Cancers (SU_13_2124)
Poster presented by Dr. Enrique Chajon Rodriguez, MD, PhD (Rennes, France)
Date: 10.21.2018
• Elderly patients: NBTXR3 as a novel treatment option in locally advanced HNSCC (MO_10_2547)
Poster presented by Dr. Valentin Calugaru, MD (Paris, France)
Date: 10.22.2018
• Exploratory Dosimetric Study of the Impact of the Pre-Radiation Therapy Intra Tumoral Injection of
Hafnium Oxide Nanoparticles Along the Radiation Treatment of Extremity and Trunk Wall Soft Tissue
Sarcomas (MO_15_2596)
Poster presented by Eliane Graulieres, PhD (Toulouse, France)
Date: 10.22.2018
• Hafnium Oxide Nanoparticle Activated by Radiation Therapy Generates an Anti-Tumor Immune
Response (1096)
Poster presented by Prof. Juliette Thariat, MD, PhD (Caen, France)
Date: 10.23 2018
About NBTXR3
NBTXR3 is a first-in-class product designed to destroy, when activated by radiotherapy:
• tumors through physical cell death
• metastasis due to immunogenic cell death leading to activation of the immune system
NBTXR3 has a high degree of biocompatibility, requires one single administration before the whole radiotherapy treatment and Nanobiotix believes has the ability to fit into current worldwide standards of radiation care.
Nanobiotix’s broad clinical program includes 10 patient population evaluated in 7 clinical trials.
In June 2018, Nanobiotix established human proof of concept for this first-in-class product in its Soft Tissue Sarcoma (STS) Phase III clinical trial.
NBTXR3 is actively being evaluated in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients that are unable to receive chemotherapy or cetuximab and have very limited therapeutic options. Promising results have been observed from the ongoing Phase I/II trial regarding the local control of the tumors.
Nanobiotix is running an Immuno-Oncology development program. In the United States, Nanobiotix has received approval from the U.S. Food and Drug Administration (FDA) to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).
The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.
The first market authorization process (CE Marking) is ongoing in Europe in the STS indication.